Inventor profile of:

Pierre CHARNEAU

City:

Paris

Country:

France

Published Applications:

51

Last publication date:

2026-04-23

Top Assignees for applications by Pierre CHARNEAU

The entities that hold a legal rights for patent applications filed by inventor CHARNEAU Pierre:

Recent patent applications by CHARNEAU Pierre

Pierre CHARNEAU from Paris, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-23
US20260108591A1
Human necessities

Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host

#2 | 2026-04-09
US20260097108A1
Human necessities

POLYNUCLEOTIDES AND LENTIVIRAL VECTORS EXPRESSING NON-STRUCTURAL ANTIGENS OF A FLAVIVIRUS SELECTED FROM THE GROUP OF DENV, ZIKV AND YFV, INDUCING PROTECTIVE CD8+ T-CELL IMMUNITY IN A HOST

#3 | 2025-10-16
US20250319173A1
Human necessities

LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST

#4 | 2025-03-20
US20250090655A1
Human necessities

BOOSTING SARS-COV-2 IMMUNITY WITH A LENTIVIRAL-BASED NASAL VACCINE

#5 | 2024-12-19
US20240415951A1
Human necessities

LENTIVIRAL VECTOR FOR EXPRESSION OF HUMAN PAPILLOMAVIRUS (HPV) ANTIGENS AND ITS IMPLEMENTATION IN THE TREATMENT OF HPV INDUCED CANCERS

#6 | 2024-02-15
US20240053339A1
Physics

HIGH THROUGHPUT METHODS AND PRODUCTS FOR SARS-COV-2 SERO-NEUTRALIZATION ASSAY

#7 | 2023-11-16
US20230364216A1
Human necessities

LENTIVIRAL VECTORS ENABLING ROUTING ANTIGENS TO MHC-II PATHWAY AND INDUCING CD4+ AND CD8+ T-CELL RESPONSES IN A HOST

#8 | 2023-08-17
US20230256084A1
Human necessities

SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS

#9 | 2021-06-24
US20210187089A1
Human necessities

Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host

#10 | 2020-07-23
US20200230228A1
Human necessities

Lentiviral vector-based Japanese encephalitis immunogenic composition

#11 | 2020-04-23
US20200121776A1
Human necessities

Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host

#12 | 2020-04-23
US20200121775A1
Human necessities

Functional screening of antigenic polypeptides-use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity

#13 | 2019-04-25
US20190119699A1
Chemistry; metallurgy

LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA

#14 | 2018-12-06
US20180346928A1
Chemistry; metallurgy

LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA

#15 | 2017-12-21
US20170362607A1
Chemistry; metallurgy

USE OF NON-SUBTYPE B GAG PROTEINS FOR LENTIVIRAL PACKAGING

#16 | 2017-11-09
US20170319681A1
Human necessities

Lentiviral vector-based Japanese encephalitis immunogenic composition

#17 | 2015-12-24
US20150368307A1
Chemistry; metallurgy

Lentiviral vector based immunological compounds against malaria

#18 | 2015-07-09
US20150191745A1
Chemistry; metallurgy

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

#19 | 2015-04-23
US20150111197A1
Physics

Isolated and purified strains of Chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

#20 | 2015-01-08
US20150011006A1
Chemistry; metallurgy

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

#21 | 2014-09-04
US20140248306A1
Chemistry; metallurgy

Lentiviral gene transfer vectors and their medicinal applications

#22 | 2014-08-21
US20140234908A1
Chemistry; metallurgy

Use of non-subtype B gag proteins for lentiviral packaging

#23 | 2014-02-20
US20140051148A1
Chemistry; metallurgy

Cells and methodology to generate non-segmented negative-strand RNA viruses

#24 | 2013-07-04
US20130171195A1
Chemistry; metallurgy

Lentiviral vector based immunological compounds against malaria

#25 | 2013-06-20
US20130157357A1
Chemistry; metallurgy

Lentiviral vectors for the preparation of immunotherapeutical compositions

#26 | 2012-12-13
US20120315296A1
Chemistry; metallurgy

Lentiviral gene transfer vectors and their medicinal applications

#27 | 2012-10-04
US20120252114A1
Chemistry; metallurgy

Use of triplex structure DNA in transferring nucleotide sequences

#28 | 2012-10-04
US20120252113A1
Chemistry; metallurgy

Use of triplex structure DNA in transferring nucleotide sequences

#29 | 2012-05-17
US20120122963A1
Chemistry; metallurgy

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

#30 | 2012-05-17
US20120122204A1
Chemistry; metallurgy

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

#31 | 2012-04-19
US20120095083A1
Chemistry; metallurgy

Use of triplex structure DNA in transferring nucleotide sequences

#32 | 2012-04-05
US20120082693A1
Chemistry; metallurgy

USE OF PROTEINS AND PEPTIDES ENCODED BY THE GENOME OF A NOVEL SARS-ASSOCIATED CORONAVIRUS STRAIN

#33 | 2011-10-13
US20110250650A1
Chemistry; metallurgy

Lentiviral vectors for the preparation of immunotherapeutical compositions

#34 | 2011-08-25
US20110206710A1
Chemistry; metallurgy

Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

#35 | 2011-06-28
US10313038
-

Lentiviral vectors for the preparation of immunotherapeutical compositions

#36 | 2011-04-14
US20110086065A9
Human necessities

Lentiviral vector-based vaccine

#37 | 2011-03-17
US20110065089A1
Chemistry; metallurgy

Strain of SARS-associated coronavirus and applications thereof

#38 | 2010-11-25
US20100297168A1
Chemistry; metallurgy

Lentiviral gene transfer vectors and their medicinal applications

#39 | 2010-09-02
US20100221820A1
Chemistry; metallurgy

Use of triplex structure DNA in transferring nucleotide sequences

#40 | 2010-06-10
US20100144040A1
Chemistry; metallurgy

Cells and methodology to generate non-segmented negative-strand RNA viruses

#41 | 2010-03-04
US20100055105A1
Physics

Novel Isolated And Purified Strains Of Chikungunya Virus And Polynucleotides And Polypetide Sequences, Diagnostic And Immunogenical Uses Thereof

#42 | 2010-02-04
US20100028382A1
Human necessities

Lentiviral vector-based vaccine

#43 | 2009-08-27
US20090214589A1
Chemistry; metallurgy

Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

#44 | 2008-10-23
US20080261197A1
Chemistry; metallurgy

Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens

#45 | 2008-05-01
US20080102057A1
Physics

BIPOTENTIAL LIVER CELL LINES FROM WILD-TYPE MAMMALIAN LIVER TISSUE

#46 | 2007-09-27
US20070224679A1
Chemistry; metallurgy

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

#47 | 2007-06-07
US20070128224A1
Chemistry; metallurgy

Strain of SARS-associated coronavirus and applications thereof

#48 | 2007-04-19
US20070087354A1
Chemistry; metallurgy

Lentiviral vector-based vaccine

#49 | 2007-01-02
US10026741
-

Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens

#50 | 2006-02-23
US20060040347A1
Chemistry; metallurgy

Use of triplex structure DNA in transferring nucleotide sequences

#51 | 2005-04-07
US20050074876A1
Physics

Bipotential liver cell lines from wild-type mammalian liver tissue

InventorID:

299958 ⎘